Skip to Main Content

ESSENTIALS OF DIAGNOSIS

  • Recurrent epistaxis.

  • Mucocutaneous telangiectases.

  • Visceral arteriovenous malformations (especially lung, liver, brain, bowel).

CLINICAL FINDINGS

A. Symptoms and Signs

Hereditary hemorrhagic telangiectasia (HHT), formerly termed “Osler-Weber-Rendu syndrome,” is an autosomal dominant disorder of development of the vasculature. Epistaxis may begin in childhood or later in adolescence. Punctate telangiectases of the lips, tongue, fingers, and skin generally appear in later childhood and adolescence. Arteriovenous malformations (AVMs) can occur at any age in the brain, lungs, and liver. Bleeding from the gastrointestinal tract is due to mucosal vascular malformations (eFigures 40–7 and 40–8) and usually is not a problem until mid-adult years or later. Pulmonary AVMs can cause hypoxemia (with peripheral cyanosis, dyspnea, and clubbing) and right-to-left shunting (with embolic stroke or brain abscess). The criteria for diagnosis require presence of three of the following four features: (1) recurrent epistaxis, (2) visceral AVMs, (3) mucocutaneous telangiectases, and (4) being the near relative of a clearly affected individual. Mutation analysis can be used for presymptomatic diagnosis or exclusion of the worry of HHT.

eFigure 40–7.

Hereditary hemorrhagic telangiectasias (HHT): Multiple diffuse telangiectasias are noted in the stomach of this patient who had epistaxis, persistent iron deficiency anemia, and cerebral arteriovenous malformations, as well as a strong family history of HHT. (Used with permission from Michelle Nazareth, MD.)

eFigure 40–8.

Hereditary hemorrhagic telangiectasias: Note that the telangiectasias have been treated with argon plasma photocoagulation. (Used with permission from Michelle Nazareth, MD.)

B. Laboratory Findings

MR or CT arteriography detects AVMs. Mutations in at least five genes can cause HHT. Three have been identified, and molecular analysis to identify them is available; these mutations in ENG, ALK1, and SMAD4 account for about 87% of families with HHT. When the familial mutation is known, molecular testing is far more cost effective than repeated clinical screening of relatives who are at risk.

PREVENTION

Embolization of pulmonary AVMs with wire coils or other occlusive devices reduces the risk of stroke and brain abscess. Treatment of brain AVMs reduces the risk of hemorrhagic stroke. All patients with HHT with evidence of a pulmonary shunt should practice routine endocarditis prophylaxis (see Table 33–5). All intravenous lines (except those for transfusion of red blood cells and radiographic contrast) should have an air-filter to prevent embolization of an air bubble. Prenatal diagnosis through mutation detection is possible.

TREATMENT

All patients in whom the diagnosis of HHT is considered should have an MRI of the brain with contrast. A contrast echocardiogram will detect most pulmonary AVMs when “bubbles” appear on the left side of the heart after 3–6 cardiac cycles. A positive ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.